Abstract
Hypogonadotropic hypogonadism (HH) is one of the least common etiologies for female infertility, although treatment in most cases leads to successful conception. The development of urinary-derived gonadotropins (hMG) a few decades ago paved the way to replacing the absent endogenous hormones (1, 2). Other alternatives to therapy include native GnRH or recombinant FSH, although the use of the time-honored hMG preparations leads in most cases to ovulation (3). It is of interest that the average treatment duration and the number of ampules used are higher compared with patients with other etiologies of infertility (2). This may be explained by the “dormant” ovaries that need to be primed before follicular response is achieved.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
